862287-35-2Relevant academic research and scientific papers
USE OF 3,1IB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF SYMPTONS OF HUNTINGTON' S DISEASE
-
Page/Page column 33; 34, (2008/06/13)
The invention provides 3,1 lb-cis-dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington''s disease in a patient, and more particularly a symptom selected from involuntary movements such as involuntary chorea, tremors and twitches, and degeneration in gait.
3, HB CIS DIHYDROTETRABANEZINE FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHOSES
-
Page/Page column 34-35, (2008/06/13)
The invention provides the use of 3,1l b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis or treatment of schizophrenia and other psychoses.
3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION
-
Page/Page column 38-39, (2008/06/13)
The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,1lb-cis-dihydrotetrabenazine or a pharmaceutically acceptable sal
DIHYDROTETRABENAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Page/Page column 17; 30-31, (2008/06/13)
The invention provides novel isomers of dihydrotetrabenazine, individual enantiomers and mixtures thereof wherein the dihydrotetrabenazine is a 3,11 b-cis- dihydrotetrabenazine. Also provided are methods for the preparation of the novel isomers, pharmaceutical compositions containing them and their use in treating hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.
